Skip to main content

Drug Interactions between Fabrazyme and migalastat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

agalsidase beta migALAstat

Applies to: Fabrazyme (agalsidase beta) and migalastat

GENERALLY AVOID: Coadministration with migalastat may significantly increase the plasma concentrations of agalsidase. Limited data have shown that coadministration of a single dose of migalastat and a standard enzyme replacement therapy infusion increased exposure to agalsidase by up to 5-fold. Agalsidase had no effect on the pharmacokinetics of migalastat.

MANAGEMENT: Migalastat is not intended for concomitant use with enzyme replacement therapy and should not be used with agalsidase.

References (1)
  1. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink

Drug and food interactions

Moderate

migALAstat food

Applies to: migalastat

ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of migalastat. When migalastat was administered one hour before a high-fat (850 calories; 56% from fat) or light meal (507 calories; 30% from fat), or one hour after a light meal, mean migalastat peak plasma concentration (Cmax) decreased by 15% to 39% and systemic exposure (AUC) decreased by 37% to 42% compared to administration in the fasting state.

MANAGEMENT: Migalastat should be taken on an empty stomach. Patients should avoid eating for at least 2 hours before and 2 hours after taking migalastat to give a minimum 4 hours fast. Clear liquids can be consumed during this 4-hour period.

References (2)
  1. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  2. (2018) "Product Information. Galafold (migalastat)." Amicus Therapeutics U.S., Inc.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Agents for fabry disease

Therapeutic duplication

The recommended maximum number of medicines in the 'agents for Fabry disease' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'agents for Fabry disease' category:

  • Fabrazyme (agalsidase beta)
  • migalastat

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer